Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM.

The study found that topical application of NS2 cream to three-dimensional human skin equivalents lowered malondialdehyde (MDA) levels induced by dry skin conditions, and topical application of NS2 eye drops to three-dimensional human cornea-like tissue lowered MDA levels induced by dry eye conditions.

President and CEO of Aldeyra Todd C. Brady, MD, PhD said in a statement, "We are excited to present the findings of our recent studies at this year's SID Annual Meeting. These data demonstrate that our lead product candidate NS2 has the ability to trap free aldehydes and may thereby protect specific lipids critical to preserving moisture in the skin and eye. Given the results that we have seen, we believe that NS2 can be a viable and effective therapeutic option for patients who suffer from dry skin or dry eye conditions."